In addition, there was one phase I clinical trial, which treated advanced colorectal carcinoma (CRC) patients with autologous ascites-derived exosomes (ASexos) either alone or in combination with GM-CSF [82]. This evidence concerns the gene CSF2 and colorectal carcinoma.